Home > Insider Trading > Filing (0001209191-19-054622)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
879169	Incyte Corp	INCY	Services-Commercial Physical & Biological Research (8731)	943136539

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1624033	Yao Wenqing	1801 Augustine Cut-Off Wilmington DE 19803	Evp, Head Of Discovery Chem	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-10-29	2,040	$18.32	47,348	No	4	M	Direct
Common Stock	Disposition	2019-10-29	2,040	$85.00	45,308	No	4	S	Direct
Common Stock	Disposition	2019-10-30	50,000	$0.00	95,308	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2019-10-29	2,040	$0.00	2,040	$18.32

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
60,502		2020-02-08	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on October 30, 2019. The performance shares vest 100% on the third anniversary of the grant date of June 28, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical milestones determined by the Issuer's Compensation Committee in October 2019 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 100% of the number of performance shares awarded, and the performance criteria was achieved at the 100% level.
This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earnedperformance stock units that have not vested.
Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years